Parker, Margaret M.
Damrauer, Scott M.
Tcheandjieu, Catherine
Erbe, David
Aldinc, Emre
Hawkins, Philip N.
Gillmore, Julian D.
Hull, Leland E.
Lynch, Julie A.
Joseph, Jacob
Ticau, Simina
Flynn-Carroll, Alexander O.
Deaton, Aimee M.
Ward, Lucas D.
Assimes, Themistocles L.
Tsao, Philip S.
Chang, Kyong-Mi
Rader, Daniel J.
Fitzgerald, Kevin
Vaishnaw, Akshay K.
Hinkle, Gregory
Nioi, Paul
Funding for this research was provided by:
Alnylam Pharmaceuticals
U.S. Department of Veterans Affairs (IK2-CX001780, I01-BX003362l)
Article History
Received: 8 February 2021
Accepted: 21 May 2021
First Online: 2 June 2021
Competing interests
: M.M.P., D.E., E.A., S.T., K.F., A.K.V., and A.O.F.-C. are employees and stockholders of Alnylam Pharmaceuticals. A.M.D., L.D.W., and P.N. are employees and stockholders of Alnylam Pharmaceuticals and former employees of Amgen Inc. G.H. is an employee and stockholder of Alnylam Pharmaceuticals, reports personal fees from 54gene, and has a patent US8168775B2 issued. S.M.D. reports grants from U.S. Department of Veterans Affairs and RenalytixAI, and personal fees from Calico Labs. P.N.H. reports personal fees from Alnylam Pharmaceuticals. J.D.G. reports grants and personal fees from Alnylam Pharmaceuticals, and personal fees from Akcea and Eidos Therapeutics. J.A.L. is an employee with the federal government, Department of Veterans Affairs, and has received grants from the Department of Veteran Affairs. J.J. has received research grants from U.S. Department of Veteran Affairs Office of Research and Development, Novartis, Kowa, Otsuka, and Amgen. P.S.T. reports grants from U.S. Department of Veteran Affairs Office of Research and Development. K.-M.C. is an employee with the Federal Government, Department of Veterans Affairs, has research funding from the Department of Veteran Affairs, and serves on the scientific advisory board for Arbutus, Inc. D.J.R. reports personal fees from Alnylam Pharmaceuticals, Novartis, and Pfizer. C.T., L.E.H., and T.L.A. have nothing to disclose.